<DOC>
	<DOC>NCT00334152</DOC>
	<brief_summary>This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.</brief_summary>
	<brief_title>Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea and Vomiting</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criteria: History of PONV (postoperative nausea and vomiting) and/or motion sickness. Have not smoked for the last 6 months. Having certain abdominal, breast, thyroid or shoulder surgery. Exclusion criteria: Pregnant or breastfeeding. Have certain preexisting medical conditions or take certain medications.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NK-1</keyword>
	<keyword>antiemetics</keyword>
	<keyword>casopitant mesylate</keyword>
	<keyword>postoperative nausea and vomiting</keyword>
	<keyword>ondansetron hydrochloride</keyword>
	<keyword>5HT3</keyword>
	<keyword>ZOFRAN</keyword>
	<keyword>PONV</keyword>
</DOC>